Biomarkers in advanced prostate cancer: Liquid biopsy, ctDNA, and more
February 10th 2025"The management of advanced prostate cancer has evolved significantly, driven in part by the integration of diverse biomarkers that guide treatment decisions from diagnosis through progression," says Nedim Ruhotina, MD.
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
January 30th 2025“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
Investigators identify potential dual targets in prostate cancer
December 20th 2024“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.